Mucor infections in humans are known as mucormycosis or zygomycosis, and can be serious and potentially life-threatening if left untreated. Mucormycosis is triggered by molds called Mucoromycetes. It is a rare, difficult-to-diagnose, and non-communicable disease that might affect the mucous membrane in the lungs, brain, eyes, skin, etc. Early diagnosis and treatment are essential for recovery. Mucormycosis treatment typically combines antifungal medication with surgical debridement. The specific approach to treatment depends on the level of the fungal infection. Knowledge regarding the side effects of drugs used for treatment is limited. Potential side effects of these drugs should be carefully weighed against their therapeutic benefits, and treatment should be tailored to the individual's specific circumstances. In this study, ProTox-II was used for the in silico estimation of toxicity levels of the recommended medications for mucormycosis using toxicity endpoints such as hepatotoxicity, cytotoxicity, carcinogenicity, mutagenicity and immunotoxicity. A close monitoring and management of potential side effects will ensure optimal outcomes in management of this life-threatening disease.